Quantcast New Device Outpaces Competition In Epilepsy Market
Search by tag or site Login to my blog ? Start my own blog














TheMoneyBlogs
Home
About
Create your own blog
Contact us
Vote for this blog!

BioHealth Investor

BioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network.

New Device Outpaces Competition In Epilepsy Market

Posted on 05/26/2007 17:05:28 | Link | Post Comment
by Sara Calabro
Med Tech Sentinel




A new device for epilepsy patients being developed by Mountain View, CA-based NeuroPace was featured this week in Technology Review. The company’s responsive neurostimulation (RNS) system is designed to help epilepsy patients who are unresponsive to drugs. NeuroPace estimates that about 2.5 million Americas are affected by epilepsy, and roughly 40-50% of those are either unresponsive to medications or experience intolerable side effects.

Implanted in the skull, the RNS device detects abnormal electrical activity in the brain and responds by delivering electrical stimulation to normalize brain activity before the patient experiences seizure symptoms.

“The idea is to stop the seizure before it occurs,” NeuroPace CEO Frank Fischer tells Technology Review.

The article points out that privately held NeuroPace is not the first company to experiment with using electricity to treat neurological disorders. Cyberonics‘ (CYBX) Vagus Nerve Stimulator, for example, is implanted under the skin near the collarbone and connected through a wire to the vagus nerve in the neck; electrical signals travel along the nerve to the brain at regular intervals. Medtronic (MDT) also is in the game with an implantable electrode that’s currently approved for Parkinson’s and in trials for use in epilepsy patients.

NeuroPace’s device might have an edge, however, because the electrical pulses delivered by RNS are not continuous; they’re only released when the device senses abnormal brain activity. Nor does RNS cause hoarseness in patients, a common side effect of the Vagus Nerve Stimulator.



Source: Med Tech Sentinel
_____________________
Stock Quote or
Examples
Morpheus Trading - Sun Aug 24, 2008 06:22AM
NOTE: Please click on the charts below to enlarge them if [read more]
Morpheus Trading - Thu Aug 28, 2008 02:39AM
NOTE: Please click on the charts below to enlarge them if [read more]
Boucher On The Big Picture - Thu Aug 28, 2008 05:01PM
Market Needs to Show Volume and Breadth To Signal Next M [read more]

PREMIER SPONSORED LINKS

Most Visited Blogs | Most Popular Blogs | Most Recent Blogs | Contact Us | Terms and conditions | Privacy Policy

The columns, articles, message board posts and any other features provided on TheMoneyBlogs.com are provided for personal finance, education and investment information and are not to be construed as investment advice. Under no circumstances does the information in this content represent a recommendation to buy, sell or hold any security. The views and opinions expressed in an article or column are the author's own and not necessarily those of TheMoneyBlogs.com and there is no implied endorsement by TheMoneyBlogs.com of any advice or trading strategy. The analysts and employees or affiliates of TheMoneyBlogs.com may hold positions in the stocks or industries discussed here. Your use of this and all information contained on TheMoneyBlogs.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

Copyright © 2008 The Connors Group, Inc.